Luminopia One Amblyopia Vision Improvement Study

NCT ID: NCT03608150

Last Updated: 2024-03-20

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

117 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-01-16

Study Completion Date

2020-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The objective of the study is to demonstrate the safety and efficacy of Luminopia One in amblyopia patients with amblyopia associated with anisometropia and/or with mild strabismus.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The proposed study is a multi-center randomized controlled clinical trial which compares the mean change in amblyopic eye Best Corrected Visual Acuity from baseline with Luminopia One ("therapeutic") to refractive correction ("control"). One-hundred and forty participants (n = 140) aged 4-7 years will be enrolled. Participants will be randomized 1:1 to the "therapeutic group ", to use Luminopia One, or the "control group", to undergo continued refractive correction, for 12 weeks of treatment.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Amblyopia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Therapeutic Group

Participants assigned to the therapeutic group will be prescribed Luminopia One for 1 hour per day, 6 days per week for 12 weeks.

Group Type EXPERIMENTAL

Luminopia One

Intervention Type DEVICE

Luminopia One is a virtual-reality based digital therapeutic that applies therapeutic modifications in real-time to cinematic content to rebalance visual input and treat amblyopia.

Control Group

Participants assigned to the control group will wear their current refractive correction full-time for 12 weeks.

Group Type ACTIVE_COMPARATOR

Refractive Correction

Intervention Type DEVICE

Standard of care refractive correction (ex. spectacles)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Luminopia One

Luminopia One is a virtual-reality based digital therapeutic that applies therapeutic modifications in real-time to cinematic content to rebalance visual input and treat amblyopia.

Intervention Type DEVICE

Refractive Correction

Standard of care refractive correction (ex. spectacles)

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age 4 to 7 years at the time of consent.
* Amblyopia associated with anisometropia and/or mild strabismus.
* Current refractive correction worn for at least 16 weeks or until 2 consecutive visual acuity measurements at least 8 weeks apart do not change by more than 1 logMAR lines.
* Amblyopic eye best-corrected visual acuity (BCVA) 20/40 to 20/200 inclusive.
* Fellow eye BCVA 20/32 or better.
* Interocular difference ≥ 3 logMAR lines.
* Heterotropia ≤ 5 prism diopters in current refractive correction at distance measured by SPCT.

Exclusion Criteria

* Atropine treatment in the past 2 weeks.
* Prior amblyopia treatment (other than refractive correction) for \> 12 months in total.
* High myopia, previous intraocular / refractive surgery, severe ocular co-morbidities or development / cognitive delay.
* History of low adherence with amblyopia treatment or light-induced seizures.
Minimum Eligible Age

4 Years

Maximum Eligible Age

7 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Luminopia

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Scott Xiao

Role: STUDY_DIRECTOR

Luminopia

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

UCLA Jules Stein Eye Institute

Los Angeles, California, United States

Site Status

Family Focus Eye Care

Gainesville, Florida, United States

Site Status

Eye Physicians of Central Florida

Maitland, Florida, United States

Site Status

Lurie Children's Hospital

Chicago, Illinois, United States

Site Status

IU School of Optometry

Bloomington, Indiana, United States

Site Status

Kids Eye Care of Maryland

Frederick, Maryland, United States

Site Status

Specialized Pediatric Eye Care

Beverly, Massachusetts, United States

Site Status

Children's Eye Care of Michigan

Dearborn, Michigan, United States

Site Status

Saint Louis University

St Louis, Missouri, United States

Site Status

University of Nebraska Medical Center

Omaha, Nebraska, United States

Site Status

Duke University

Durham, North Carolina, United States

Site Status

Cleveland Clinic

Cleveland, Ohio, United States

Site Status

OSU College of Optometry

Columbus, Ohio, United States

Site Status

Pediatric Ophthalmology of Erie

Erie, Pennsylvania, United States

Site Status

Conestoga Eye

Lancaster, Pennsylvania, United States

Site Status

Children's Hospital Of Philadelphia

Philadelphia, Pennsylvania, United States

Site Status

Tri-County Eye Physicians

Southampton, Pennsylvania, United States

Site Status

Houston Eye Associates

Houston, Texas, United States

Site Status

Texas Children's Hospital (BCM)

Houston, Texas, United States

Site Status

Houston Eye Associates

Houston, Texas, United States

Site Status

Rocky Mountain Eye Care

Salt Lake City, Utah, United States

Site Status

Virginia Pediatric Eye Center

Virginia Beach, Virginia, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Study Protocol

View Document

Document Type: Statistical Analysis Plan

View Document

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

C-AM-2

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Amblyopia (Lazy Eye) Treatment Study
NCT00001864 COMPLETED PHASE3
Monovision for the Treatment of Diplopia
NCT01426672 COMPLETED PHASE1
OCT-A and Amblyopia
NCT05223153 COMPLETED